المؤلفون: Shurin MR, Wheeler SE

المصدر: ImmunoTargets and Therapy, Vol Volume 13, Pp 215-234 (2024)

مصطلحات موضوعية: autoimmune diseases, autoantibodies, autoantigen, immunological disorders, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/clinical-significance-of-uncommon-non-clinical-and-novel-autoantibodie-peer-reviewed-fulltext-article-ITTTest; https://doaj.org/toc/2253-1556Test

الوصول الحر: https://doaj.org/article/34d5eb1865e74901b836f2149715f357Test

المؤلفون: Akash Pawar, Prakash Joshi, Abhishek Singhai

المصدر: Journal of Family Medicine and Primary Care, Vol 13, Iss 3, Pp 896-902 (2024)

مصطلحات موضوعية: anemia, disease activity index, erythrocyte sedimentation rate, immunological disorders, thyroid function, Medicine

وصف الملف: electronic resource

العلاقة: http://www.jfmpc.com/article.asp?issn=2249-4863;year=2024;volume=13;issue=3;spage=896;epage=902;aulast=PawarTest; https://doaj.org/toc/2249-4863Test

الوصول الحر: https://doaj.org/article/931e04a65a4946858626ee350dbd73f1Test

المؤلفون: Moslem Javidan, Amir Mohamad Amiri, Narges Koohi, Nazanin Joudaki, Mohammad Ali Bashirrohelleh, Ali Pirsadeghi, Ali Farhadi Biregani, Mohammad Rashno, Mohammad Ghasemi Dehcheshmeh, Moosa Sharifat, Ali Khodadadi, Ladan Mafakher

المصدر: Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 116983- (2024)

مصطلحات موضوعية: Tregitope, Treg epitope, TGFB, Foxp3, EpiMatrix, Immunological Disorders, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S0753332224008679Test; https://doaj.org/toc/0753-3322Test

الوصول الحر: https://doaj.org/article/5d9ef44c573c46a09016446a34855c3eTest

المؤلفون: Nikkhah, Ali, Nasehi, Mohammad Mahdi, Momtazmanesh, Nader, Etemad, Kourosh, Hajatnia, Somayeh

المصدر: Iranian Journal of Child Neurology; Vol. 18 No. 2 (2024): spring; 31-41 ; 2008-0700 ; 1735-4668

مصطلحات موضوعية: Therapeutic plasma exchange (TPE), Pediatric neuro-immunological disorders (PNID)

وصف الملف: application/pdf

العلاقة: https://journals.sbmu.ac.ir/ijcn/article/view/40139/33045Test; https://journals.sbmu.ac.ir/ijcn/article/view/40139Test

الإتاحة: https://doi.org/10.22037/ijcn.v18i1.40139Test
https://journals.sbmu.ac.ir/ijcn/article/view/40139Test

المؤلفون: T. A. Panafidina, T. V. Popkova, A. M. Lila, E. L. Nasonov, Т. А. Панафидина, Т. В. Попкова, А. М. Лила, Е. Л. Насонов

المساهمون: Настоящее исследование выполнено в рамках фундаментальной темы «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний» (1021051402790-6).

المصدر: Rheumatology Science and Practice; Vol 61, No 6 (2023); 678-688 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 678-688 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: гидроксихлорохин, clinical manifestations, immunological disorders, therapy, hydroxychloroquine, клинические проявления, иммунологические нарушения, терапия

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/3484/2344Test; Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi:10.1038/nrdp.2016.39; Costenbader KH, Schur PH. We need better classification and terminology for “people at high risk of or in the process of developing lupus”. Arthritis Care Res (Hoboken). 2015;67(5):593-596. doi:10.1002/acr.22484; Lambers WM, Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum. 2021;51(1):43-48. doi:10.1016/j.semarthrit.2020.11.006; Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней диагностики системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi:10.47360/1995-4484-2021-119-128; Лила ВА, Мазуров ВИ, Лила АМ. «Неполная» системная красная волчанка в реальной клинической практике: трудности диагностики. Терапия. 2022;2(54):86-95. doi:10.18565/therapy.2022.2.86-95; Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533. doi:10.1056/NEJMoa021933; Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi:10.1186/ar3258; Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus: What remains after application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria? Arthritis Care Res (Hoboken). 2020;72(5):607-614. doi:10.1002/acr.23894; Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277. doi:10.1002/art.1780251101; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-291.; Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27(2):373-376.; Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G, et al. Differentiating between UCTD and early-stage SLE: From definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21. doi:10.1038/s41584-021-00710-2; Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med. 1989;149(11):2473-2476.; Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al.; Study group on incomplete SLE and SLE with disease duration longer than 10 years. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001;40(1):89-94. doi:10.1093/rheumatology/40.1.89; Stahl-Hallengren CS, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus. 2004;13(2):85-88. doi:10.1191/0961203304lu477oa; Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus. 2010;19(3):239-246. doi:10.1177/0961203309351033; Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012;14(4):R174. doi:10.1186/ar3927; Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol. 1996;23(3):469-475.; Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S. Undifferentiated connective tissue diseases: The clinical and serological profiles of 91 patients followed for at least 1 year. Lupus. 1998;7(2):95-100. doi:10.1191/096120398678919787; Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol. 1998;17(3):195-201. doi:10.1007/BF01451046; Danieli MG, Fraticelli P, Franceschini F, Cattaneo R, Farsi A, Passaleva A, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. 1999;17(5):585-591.; Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol. 1999;26(4):816-825.; Cavazzana I, Franceschini F, Belfiore N, Quinzanini M, Caporali R, Calzavara-Pinton P, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: Clinical features and follow-up of 148 patients. Clin Exp Rheumatol. 2001;19(4):403-409.; Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21(3):313-320.; Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a heumatology center in Cali, Colombia: Clinical features of 94 patients followed for a year. Rheumatol Int. 2013;33(4):1085-1088. doi:10.1007/s00296-011-2234-y; García-González M, Rodríguez-Lozano B, Bustabad S, Ferraz-Amaro I. Undifferentiated connective tissue disease: Predictors of evolution into definite disease. Clin Exp Rheumatol. 2017;35(5):739-745.; Bortoluzzi A, Furini F, Campanaro F, Govoni M. Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: Analysis of a large monocentric cohort with a long-term follow-up. Lupus. 2017;26(6):616-622. doi:10.1177/0961203316671814; Zucchi D, Tani C, Monacci F, Elefante E, Carli L, Parma A, et al. Pregnancy and undifferentiated connective tissue disease: Outcome and risk of flare in 100 pregnancies. Rheumatology (Oxford). 2020;59(6):1335-1339. doi:10.1093/rheumatology/kez440; Ganczarczyk L, Urowitz MB, Gladman DD. “Latent lupus”. J Rheumatol. 1989;16(4):475-478.; Al Daabil M, Massarotti EM, Fine A, Tsao H, Ho P, Schur PH, et al. Development of SLE among “potential SLE” patients seen in consultation: Long-term follow-up. Int J Clin Pract. 2014;68(12):1508-1513. doi:10.1111/ijcp.12466; Tiao J, Feng R, Carr K, Okawa J, Werth VP. Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). J Am Acad Dermatol. 2016;74(5):862-869. doi:10.1016/j.jaad.2015.12.029; Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018;77(10):1432-1439. doi:10.1136/annrheumdis-2018-213386; Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, et al. Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020;72(1):78-88. doi:10.1002/art.41093; Sternhagen E, Bettendorf B, Lenert A, Lenert PS. The role of clinical features and serum biomarkers in identifying patients with incomplete lupus erythematosus at higher risk of transitioning to systemic lupus erythematosus: Current perspectives. J Inflamm Res. 2022;15:1133-1145. doi:10.2147/JIR.S275043; Chen Z, Li MT, Xu D, Leng XM, Wang Q, Tian XP, et al. Organ damage in patients with incomplete lupus syndromes: From a Chinese academic center. Clin Rheumatol. 2015;34(8):1383-1389. doi:10.1007/s10067-015-2884-3; Calvo-Alén J, Bastian HM, Straaton KV, Burgard SL, Mikhail IS, Alarcón GS. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum. 1995;38:1475-1484. doi:10.1002/art.1780381014; Vilá LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000;9:110-115. doi:10.1191/096120300678828073; Rúa-Figueroa Í, Richi P, López-Longo FJ, Galindo M, Calvo-Alén J, Olivé-Marqués A, et al.; EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology). Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore). 2015;94(1):e267. doi:10.1097/MD.0000000000000267; Olsen NJ, McAloose C, Carter J, Han BK, Raman I, Li QZ, et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis. 2016;2016:8791629. doi:10.1155/2016/8791629; Aberle T, Bourn RL, Munroe ME, Chen H, Roberts VC, Guthridge JM, et al. Clinical and serologic features in patients with incomplete lupus classification versus systemic lupus erythematosus patients and controls. Arthritis Care Res (Hoboken). 2017;69(12):1780-1788. doi:10.1002/acr.23201; Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819; Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):4-11. doi:10.1093/rheumatology/keaa379; Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: Новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi:10.14412/1995-4484-2020-5-14; Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, et al. Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for systemic lupus erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease. Arthritis Care Res (Hoboken). 2021;73(12):1804-1808. doi:10.1002/acr.24391; Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: История и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi:10.47360/1995-4484-2022-397-412; Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(6):1073-1085. doi:10.1002/art.41610; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi:10.47360/1995-4484-2021-367-383; Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Association of serum B cell activating factor from the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus. 2013;22(9):873-884. doi:10.1177/0961203313496302; Suso JP, Posso-Osorio I, Jiménez CA, Naranjo-Escobar J, Ospina FE, Sánchez A, et al. Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes. Lupus. 2018;27(5):708-715. doi:10.1177/0961203317739132; Slight-Webb S, Smith M, Bylinska A, Macwana S, Guthridge C, Lu R, et al. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020;146(6):1419-1433. doi:10.1016/j.jaci.2020.04.047; Munroe ME, Young KA, Kamen DL, Guthridge JM, Niewold TB, Costenbader KH, et al. Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthritis Rheumatol. 2017;69(3):630-642. doi:10.1002/art.40004; Li QZ, Zhou J, Lian Y, Zhang B, Branch VK, Carr-Johnson F, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol. 2010;159(3):281-291. doi:10.1111/j.1365-2249.2009.04057.x; Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014-2021. doi:10.1136/annrheumdis-2015-208140; Bourn R, James JA. Preclinical lupus. Curr Opin Rheumatol. 2015;27:433-439. doi:10.1097/BOR.0000000000000199; Olsen NJ, James JA, Arriens C, Ishimori ML, Wallace DJ, Kamen DL, et al. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): Study protocol for a randomized controlled trial. Trials. 2018;19(1):694. doi:10.1186/s13063-018-3076-7; James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, Walker C, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401-409. doi:10.1177/0961203307078579; Lambers WM, Westra J, Bootsma H, de Leeuw K. Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol. 2021;48(6):847-851. doi:10.3899/jrheum.200726; Durcan L, Petri M. Immunomodulators in SLE: Clinical evidence and immunologic actions. J Autoimmun. 2016;74:73-84. doi:10.1016/j.jaut.2016.06.010; Arnaud L, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192-200. doi:10.1016/j.autrev.2014.10.019; Решетняк ТМ, Кошелева НМ, Насонов ЕЛ. Системная красная волчанка и беременность: до, во время гестации и после родов. Научно-практическая ревматология. 2023;61(3):292-297. doi:10.47360/1995-4484-2023-292-297; https://rsp.mediar-press.net/rsp/article/view/3484Test

الإتاحة: https://doi.org/10.47360/1995-4484-2023-678-688Test
https://doi.org/10.1038/nrdp.2016.39Test
https://doi.org/10.1002/acr.22484Test
https://doi.org/10.1016/j.semarthrit.2020.11.006Test
https://doi.org/10.47360/1995-4484-2021-119-128Test
https://doi.org/10.18565/therapy.2022.2.86-95Test
https://doi.org/10.1056/NEJMoa021933Test
https://doi.org/10.1186/ar3258Test
https://doi.org/10.1002/art.1780251101Test
https://doi.org/10.1002/art.1780400928Test

المؤلفون: Xu, Meng, Ito-Kureha, Taku, Kang, Hyun-Seo, Raj, Timsse, Hoefig, Kai P., Hohn, Christine, Giesert, Florian, Wang, Yinhu, Pan, Wenliang, Ziętara, Natalia, Straub, Tobias, Feederle, Regina, Daniel, Carolin, Adler, Barbara, König, Julian, Feske, Stefan, Tsokos, George C., Wurst, Wolfgang, Urlaub, Henning, Sattler, Michael, Kisielow, Jan, Wulczyn, F. Gregory, Łyszkiewicz, Marcin, Heissmeyer, Vigo

المصدر: Nature Communications, 15 (1)

مصطلحات موضوعية: Immunological disorders, Lymphocyte differentiation, T-cell receptor, Thymus, VDJ recombination

وصف الملف: application/application/pdf

العلاقة: info:eu-repo/semantics/altIdentifier/wos/001183186200011; http://hdl.handle.net/20.500.11850/666257Test

الإتاحة: https://doi.org/20.500.11850/666257Test
https://doi.org/10.3929/ethz-b-000666257Test
https://doi.org/10.1038/s41467-024-46371-zTest
https://hdl.handle.net/20.500.11850/666257Test

المؤلفون: Emily Baum, Wenming Huang, Catherine Vincent-Delorme, Perrine Brunelle, Adam Antebi, Hormos Salimi Dafsari

المصدر: International Journal of Molecular Sciences, Vol 25, Iss 4, p 2053 (2024)

مصطلحات موضوعية: PUF60, neurodevelopmental disorders, Verheij syndrome, immunological disorders, Biology (General), QH301-705.5, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1422-0067/25/4/2053Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test

الوصول الحر: https://doaj.org/article/20df77b287954b629ead54e5fbb56e3dTest

المؤلفون: Yingwei Wang, Yi Jiang, Junwen Wang, Shiqiang Li, Xiaoyun Jia, Xueshan Xiao, Wenmin Sun, Panfeng Wang, Qingjiong Zhang

المصدر: Frontiers in Immunology, Vol 14 (2023)

مصطلحات موضوعية: immunological disorders, ophthalmology, hereditary, retinitis pigmentosa, exudative vitreoretinopathy, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239886/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/40cbf784c8b34ca49a1c8596df1f74cbTest

المؤلفون: Fatema Tuz Zohora, Mansur Aliyu, Ali Akbar Saboor-Yaraghi

المصدر: Heliyon, Vol 9, Iss 7, Pp e18120- (2023)

مصطلحات موضوعية: Bone marrow, Mesenchymal stem cells, Secretomes, Acellular therapy, Degenerative disorders, Immunological disorders, Science (General), Q1-390, Social sciences (General), H1-99

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2405844023053288Test; https://doaj.org/toc/2405-8440Test

الوصول الحر: https://doaj.org/article/e547cfca5a0c4a7ea867129e8a980d16Test

المؤلفون: F.B. Mirodilova, N.S. Saipova, F.Kh. Abbaskhanova

المصدر: Research Focus 2(1) 341-345

مصطلحات موضوعية: dysbiotic processes, inflammatory diseases, bacterial vaginosis, immunological disorders, hormonal homeostasis

العلاقة: https://zenodo.org/record/7594304Test; https://doi.org/10.5281/zenodo.7594304Test; oai:zenodo.org:7594304

الإتاحة: https://doi.org/10.5281/zenodo.7594304Test
https://doi.org/10.5281/zenodo.7594303Test
https://zenodo.org/record/7594304Test